Janssen Pharma: Darzalex Combo Therapy Increases Progression-Free Survival in Certain Myeloma Patients
30 Mai 2019 - 12:20AM
Dow Jones News
By Stephen Nakrosis
The Janssen Pharmaceutical Cos. of Johnson & Johnson (JNJ)
said Wednesday data from a phase 3 study showed a combination pf
Darzalex, or daratumumab, and lenalidomide and dexamethasone
resulted in a significant increase in progression-free survival in
certain multiple myeloma patients.
The study results were published in the New England Journal of
Medicine.
Janssen said the data, which came from data from the randomized,
open-label Phase 3 MAIA study, indicated the Darzalex combination
"resulted in a significant increase in progression-free survival in
patients with newly diagnosed multiple myeloma who are ineligible
for autologous stem cell transplantation."
Study results demonstrated that at a median follow-up of 28
months the treatment reduced the risk of disease progression or
death by 44% in patients with newly diagnosed multiple myeloma who
are ineligible for ASCT.
The safety of the combination in this patient population was
consistent with previously reported studies, Janssen said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 29, 2019 18:05 ET (22:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024